Crinetics Pharmaceuticals, Inc. (CRNX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$84.950.00%
Close 2026-09-02 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Intact: The reason to own it still holds.
Crinetics is growing revenue from its drug PALSONIFY. Revenue rose to $10.7M in 2026-Q1. The company aims to keep expenses between $480M and $520M in 2026. Analysts expect revenue to double next year.
Crinetics is still losing money and has volatile management. Operating costs remain high near $500M. Earnings are expected to stay negative through 2027. The recent CEO and officer changes add risk.
The price is near our fair value of $83. Analysts expect 100% revenue growth. Our view aligns with the Street on revenue but note ongoing losses.
Breaks if: free cash flow falls below $300 million in FY25
Breaks if: expenses exceed $520 million in FY26
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. The company is currently loss-making but has shown some revenue growth in its product PALSONIFY, indicating potential for future expansion.
The market seems to have low expectations for CRNX, as indicated by a low fragility tier and a premium valuation compared to peers. However, the company's recent financial performance is below that of its industry cohort, suggesting some caution is already priced in.
Management is focused on expanding commercial adoption of PALSONIFY and advancing clinical trials for atumelnant. While the trajectory shows promise, the company remains in a volatile state with elevated risk due to its loss-making status.
The long-term thesis hinges on the company's ability to maintain revenue growth and successfully advance its clinical programs. Additionally, broader market conditions, such as the performance of sector bellwethers and economic indicators, will play a crucial role.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports this improved outlook. There are no new threats affecting the thesis.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Maintain non-GAAP operating expenses between $480 million and $520 million for the fiscal year 2026.
Breaks if: PALSONIFY revenue falls below $5 million in 2026-Q1
Over the next 1 to 3 years, CRNX's path will depend on its execution of strategic priorities and external market factors. Not investment advice.